Evidence brief · printable

Metabolic Dysfunction-Associated Steatohepatitis evidence brief

One page, every section sourced. Print it or bring it on your phone.

  1. Research Tracker
  2. Evidence briefs
  3. Metabolic Dysfunction-Associated Steatohepatitis

Print or save as PDF Fits on one A4 or Letter page.

Metabolic Dysfunction-Associated Steatohepatitis: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/metabolic-dysfunction-associated-steatohepatitis.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Efimosfermin alfa 3 trials
  • ALN-PNP 2 trials
  • ECC4703 2 trials
  • Efruxifermin 2 trials
  • Miricorilant 2 trials
  • Pegozafermin 2 trials

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Fasting and time-restricted eating 4 trials · 1 completed · 1 with results
  • Nutrition counselling and food-based products 3 trials · 2 completed · 0 with results
  • Education, coaching and self-management 3 trials · 1 completed · 0 with results
  • Probiotics, prebiotics and synbiotics 3 trials · 1 completed · 0 with results
  • Psychotherapy, counselling and peer support 2 trials · 1 completed · 0 with results
  • NAD+ precursors (nicotinamide riboside, NMN) 1 trials · 1 completed · 0 with results

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic… NCT07631637
  • A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With… NCT06419374
  • A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With… NCT06318169
  • Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification,… NCT06944353
  • The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in… NCT06717828
  • Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic… NCT06768216

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Supplements and nutraceuticals: inflammation and other biomarkers 8 trials, no results posted yet
  • Diet, fasting and nutrition: weight and metabolic markers 5 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (38 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.